G7 Acetabular System With Vivacit-E or Longevity Liner PMCF Study

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorZimmer Biomet

About this trial

The main objectives of this study are to confirm the long-term safety, performance, and clinical benefits of the G7 Acetabular Shells when used with the Vivacit-E and Longevity HXLPE liners and instrumentation in primary and revision total hip arthroplasty.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Patient must be a legal adult who has reached full skeletal maturity.

Noninflammatory degenerative joint disease including osteoarthritis and avascular necrosis

Rheumatoid arthritis

Correction of functional deformity

Disqualifiers

Patient presents with osteoporosis, which in the opinion of the Principal Investigator, may limit the subject's ability to support total hip arthroplasty using the study device.

Patient has a metabolic disorder that may impair bone formation.

Patient has osteomalacia.

Patient has distant foci of infections which may spread to the implant site or patient with infection, sepsis or osteomyelitis.

Trial design

Design model

Single group

Treatments tested in this trial

  • Vivacit-E and Longevity (HXLPE) Liners

    Device

    This is a dual cohort study in which 150 subjects will receive the Vivacit-E (HXLPE) Liner and 150 subjects will receive the Longevity (HXLPE) Liner.

Treatment groups

300 Participants
are divided into 1 treatment group
Group A: G7 Shell with Vivacit-E and Longevity Highly Crosslinked Polyethylene LinersOther 1 intervention

Trial outcomes

Primary outcomes

1

Survival of the study device (liner); whether or not it is still implanted in the subject

Survivorship will be based on revision or intended revision of the study device (liner).

Time frame
At 10 years
2

Adverse Event (safety)

Safety will be evaluated by monitoring the frequency and incidence of device related adverse events or unanticipated adverse device effects in investigational subjects.

Time frame
At 10 years

Secondary outcomes

1

Pain and Function using Modified Harris Hip Score

Pain and function will be measured using the Modified Harris Hip Score self assessment. The overall score runs from 0-100 with 100 representing the best outcome.

Time frame
At 10 years
2

Pain and Function using Oxford Hip Score

Pain and function will be measured using the Oxford Hip Score self assessment. The overall score runs from 0-48 with 48 representing the best outcome.

Time frame
At 10 years
3

Patient Quality of Life using EQ-5D-5L Descriptive System

Perceived qualify of life will be measured using the EQ-5D-5L Descriptive System - comprises mobility, self care, usual activities, pain/discomfort, anxiety/depression. Each question in this section has an overall score of 1-5 with 1 representing the best health.

Time frame
At 10 years
4

Patient Quality of Life using EQ-5D-5L EQ visual analogue scale

Perceived qualify of life will be measured using the EQ visual analogue scale (EQ VAS) - records the respondent's self-rated health on a vertical, visual analogue scale. This section has an overall score of 0-100 with 100 representing the best health.

Time frame
At 10 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.